GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 autoreactive CD4 T cells

[1] Couper JJ(2018)ISPAD clinical practice consensus guidelines 2018: stages of type 1 diabetes in children and adolescents Pediatr Diabetes 19 20-27

[2] Haller MJ(2018)Peptide immunotherapy for type 1 diabetes—clinical advances Front Immunol 9 392-74

[3] Greenbaum CJ(2019)Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine Lancet Diabetes Endocrinol 7 65-327

[4] Smith EL(2011)Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial Lancet 378 319-419

[5] Peakman M(2018)Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: a randomized clinical trial Pediatr Diabetes 19 410-49

[6] Roep BO(2017)GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis Diabetologia 60 43-3424

[7] Wheeler DCS(2013)Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial Diabetes Care 36 3418-1278

[8] Peakman M(2012)Decreased GAD Diabet Med 29 1272-6454

[9] Wherrett DK(1999)-specific Th1/Tc1 phenotype in children with type 1 diabetes treated with GAD-alum J Immunol 163 6448-145

[10] Bundy B(1989)Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling Cell Immunol 121 134-293

[1] Couper JJ(2018)ISPAD clinical practice consensus guidelines 2018: stages of type 1 diabetes in children and adolescents Pediatr Diabetes 19 20-27

[2] Haller MJ(2018)Peptide immunotherapy for type 1 diabetes—clinical advances Front Immunol 9 392-74

[3] Greenbaum CJ(2019)Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine Lancet Diabetes Endocrinol 7 65-327

[4] Smith EL(2011)Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial Lancet 378 319-419

[5] Peakman M(2018)Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: a randomized clinical trial Pediatr Diabetes 19 410-49

[6] Roep BO(2017)GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis Diabetologia 60 43-3424

[7] Wheeler DCS(2013)Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial Diabetes Care 36 3418-1278

[8] Peakman M(2012)Decreased GAD Diabet Med 29 1272-6454

[9] Wherrett DK(1999)-specific Th1/Tc1 phenotype in children with type 1 diabetes treated with GAD-alum J Immunol 163 6448-145

[10] Bundy B(1989)Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling Cell Immunol 121 134-293